Uterine sarcomas: Review of 26 years at The Instituto Nacional de Cancerologia of Mexico

作者: David Cantú de León , Heliodoro González , Delia Pérez Montiel , Jaime Coronel , Carlos Pérez-Plasencia

DOI: 10.1016/J.IJSU.2013.04.013

关键词:

摘要: Abstract Uterine sarcomas are a group of uncommon tumors that account for approximately 1% malignant neoplasms the female genital tract and between 3 8.4% uterine neoplasms. Objective To evaluate factors associated with clinical behavior sarcomas. Materials methods In period from October 1983 to December 2009, files patients confirmed diagnosis sarcoma at National Institute Cancerology Mexico (INCan) were reviewed evaluated. Results We identified 77 cases complete information; average age presentation was 51.6 years (range, 14–78 years); most frequent histology leiomyosarcoma (LMS) in 53/77 (68.8%) cases; symptom reported time abnormal vaginal bleeding 36/77 (46.7%) cases, stage (CS) I 31/77 (40.2%) cases. Initial treatment total abdominal hysterectomy (TAH) bilateral salpingo-oophrectomy (BSO) (68.9%) Disease-free 27.8 months 0–184 months), disease recurrence 33/77 (42.85%) site as lung 13/33 (39.39%) Management recurrences surgery chemotherapy (CT) 5/33 (15.15%) CT 10/33 (30.30%) At present, 40.3% (31/77) found be Disease-free. Conclusion Notwithstanding aggressive neoplasms, accepted management date is TAH + BSO, observing fact this procedure not performed by oncologists does affect DFP nor OS, contrary what occurs other gynecological

参考文章(26)
Zagouri F, Papadimitriou Ca, Dimopoulos Am, Linardou H, Management of advanced stage uterine sarcomas: a bone of contention. European Journal of Gynaecological Oncology. ,vol. 30, pp. 483- 492 ,(2009)
Asher Shushan, Abraham Benshushan, Javier Mejia-Gomez, Inbar Ben-Shachar, Yael Naaman, David Shveiky, Uterine sarcoma: prognostic factors and treatment evaluation. Israel Medical Association Journal. ,vol. 13, pp. 76- 79 ,(2011)
Peter Devilee, Fattaneh A. Tavassoli, Pathology and Genetics of Tumours of the Breast and Female Genital Organs World Hhealth Organization Classification of Tumours. ,(2003)
N.S. Reed, C. Mangioni, H. Malmström, G. Scarfone, A. Poveda, S. Pecorelli, S. Tateo, M. Franchi, J.J. Jobsen, C. Coens, I. Teodorovic, I. Vergote, J.B. Vermorken, Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874) European Journal of Cancer. ,vol. 44, pp. 808- 818 ,(2008) , 10.1016/J.EJCA.2008.01.019
Sandra E Brooks, Min Zhan, Timothy Cote, Claudia R Baquet, Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecologic Oncology. ,vol. 93, pp. 204- 208 ,(2004) , 10.1016/J.YGYNO.2003.12.029
Jeff F. Lin, Brian M. Slomovitz, Uterine sarcoma 2008 Current Oncology Reports. ,vol. 10, pp. 512- 518 ,(2008) , 10.1007/S11912-008-0077-9
Charles A. Leath, Warner K. Huh, Johnny Hyde, David E. Cohn, Kimberly E. Resnick, Nicholas P. Taylor, Matthew A. Powell, David G. Mutch, William H. Bradley, Melissa A. Geller, Peter A. Argenta, Michael A. Gold, A multi-institutional review of outcomes of endometrial stromal sarcoma Gynecologic Oncology. ,vol. 105, pp. 630- 634 ,(2007) , 10.1016/J.YGYNO.2007.01.031
Angiolo Gadducci, Stefania Cosio, Antonella Romanini, Andrea Riccardo Genazzani, The management of patients with uterine sarcoma: a debated clinical challenge. Critical Reviews in Oncology Hematology. ,vol. 65, pp. 129- 142 ,(2008) , 10.1016/J.CRITREVONC.2007.06.011
Joo-Hyun Nam, Jeong-Yeol Park, Update on treatment of uterine sarcoma. Current Opinion in Obstetrics & Gynecology. ,vol. 22, pp. 36- 42 ,(2010) , 10.1097/GCO.0B013E328334D90F